Mesoblast
MESO
$6.15
Share price
-1.13%
Change (1 day)
83.04%
Change (1 year)
Categories
P/S ratio for Mesoblast (MESO)
P/S ratio as of April 2024 (TTM): 93.5
According to Mesoblast 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 93.5257. At the end of 2023 the company had a P/S ratio of 84.8.
P/S ratio history for Mesoblast from 2015 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 84.8 | 48.53% |
| 2022 | 57.1 | -14.68% |
| 2021 | 66.9 | 7.44% |
| 2020 | 62.3 | 68.44% |
| 2019 | 37.0 | 44.6% |
| 2018 | 25.6 | -23.74% |
| 2017 | 33.5 | 173.14% |
| 2016 | 12.3 | -42.59% |
| 2015 | 21.4 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
 NRC Health
NRC | 5.40 | -94.23% | 🇺🇸 USA |